Hidden hepatitis B and HIV reactivation with long-acting therapy
Part of Digestive system, Immune system & allergy, Infections clinical trials.
This study looks at people with HIV who also have a hidden form of hepatitis B (occult HBV). It checks if switching to a long-acting HIV treatment might cause the hepatitis B to become active again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have HIV and have been on stable HIV treatment for at least 6 months.
- You have had a positive antibody test for hepatitis B core (HBcAb) but no current hepatitis B surface antigen (HBsAg).
- Your HIV treatment does not have resistance to certain drug classes (integrase inhibitors and NNRTIs).
- Your lowest-ever CD4 count (CD4 nadir) was above 200 cells/mm3.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
This study tests whether people with both HIV and hepatitis B (HBV) can safely stop or switch parts of their antiviral treatment. It aims to see if simpler treatment can keep both viruses under control for 96 weeks.
This study tracks patients who carry hepatitis B antibodies and are about to start immunosuppressive therapy (medications that weaken the immune system). Researchers want to understand when and how hepatitis B can reactivate in these patients and how to prevent it.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This study looks at a planned, supervised “treatment interruption” period for people with HIV who are very well controlled on HIV medicines. It mainly aims to understand what happens when therapy is paused and how to reduce the risk of passing HIV to others.
Hear when a new HBV (Hepatitis B Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.